

UCB Pharma

[View the current UCB Pharma Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/10415-UCB+Pharma.html)

(<http://www.bioportfolio.com/biocorporate/10415-UCB+Pharma.html>)

Contact Details:

**Chemin du Foriest
Braine l'Alleud**

Tel: 00 32 2 386 2111
Fax: 00 32 2 386 2704
Email:

**B-1420
Belgium**

Recent Publications by UCB Pharma:



- [A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis.](#)
*The American College of Rheumatology (ACR) 20% preliminary definition of...*10th October, 2009
Pharmacometrics, Department of Global Exploratory Development, UCB Pharma- Clin Pharmacol Ther. 2009 Oct;86(4):387-95. Epub 2009 Jul 22. ([DOI Direct Link](#))
- [The inhibitory avoidance test optimized for discovery of cognitive enhancers.](#)
*In the present article, we describe a new protocol for the inhibitory...*2nd October, 2009
CNS Pharmacology Department-Cognitive Psychopharmacology, UCB Pharma,- Behav Res Methods. 2009 Aug;41(3):805-11. ([DOI Direct Link](#))
- [A risk-based analysis of the AAPS conference report on quantitative bioanalytical methods validation and implementation.](#)
*The 3rd American Association of Pharmaceutical Scientists (AAPS)/Food and...*25th September, 2009
UCB Pharma, Exploratory Statistics, Braine L'Alleud, Belgium.- J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 1;877(23):2235-43. ([DOI Direct Link](#))
- [Brivaracetam inhibits spreading depression in rat neocortical slices in vitro.](#)
*Epilepsy and migraine are episodic neurological disorders with marked...*11th September, 2009
UCB Pharma SA, CNS Research, Braine-l'Alleud, Belgium.- Seizure. 2009 Jul;18(6):453-6. Epub 2009 Feb 10. ([DOI Direct Link](#))
- [Profile of the new pyrrolidone derivative seletracetam \(ucb 44212\) in animal models of epilepsy.](#)
*Seletracetam is a pyrrolidone derivative with a one-log-unit higher...*26th August, 2009
CNS Research, UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l'Alleud,- Eur J Pharmacol. 2009

Jul 1;614(1-3):30-7. Epub 2009 Apr 19. ([DOI Direct Link](#))

- [Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques.](#)
*The safety profiles of once-daily adjunctive levetiracetam (LEV) extended...*25th August, 2009
G3P Epidemiology, UCB Pharma S.A., Brussels, Belgium.- *Epilepsy Behav.* 2009 Oct;16(2):240-5.
Epub 2009 Aug 20. ([DOI Direct Link](#))
- [Pharmacokinetics of levetiracetam XR 500mg tablets.](#)
*PURPOSE: To compare the relative bioavailability of levetiracetam...*25th July, 2009
UCB Pharma S.A., Braine-l'Alleud, Belgium.- *Epilepsy Res.* 2009 Apr;84(2-3):224-31. Epub 2009 Mar 4. ([DOI Direct Link](#))
- [Repeated assessment of cardiovascular and respiratory functions using combined telemetry and whole-body plethysmography in the rat.](#)
*INTRODUCTION: As the currently recommended laboratory techniques for...*21st July, 2009
Department of Non Clinical Development, Non Clinical Safety Pharmacology- *J Pharmacol Toxicol Methods.* 2009 Sep-Oct;60(2):117-29. Epub 2009 Jul 17. ([DOI Direct Link](#))
- [Gender and interindividual variability in pharmacokinetics.](#)
*Like any other drugs, antiallergic medications can be associated with...*16th July, 2009
UCB Pharma SA, Chemin du Foriest, Braine l' Alleud, B-1420 Belgium.- *Drug Metab Rev.* 2009;41(3):408-21. ([DOI Direct Link](#))
- [Physiologically based pharmacokinetics \(PBPK\).](#)
*Allometric scaling is widely used to predict human pharmacokinetic...*16th July, 2009
UCB Pharma SA, Belgium.- *Drug Metab Rev.* 2009;41(3):391-407. ([DOI Direct Link](#))
- [Drug metabolism and pharmacokinetics.](#)
*In this article, aspects of absorption, distribution, metabolism, and...*16th July, 2009
UCB- *Drug Metab Rev.* 2009;41(3):344-90. ([DOI Direct Link](#))
- [Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.](#)
*Summary Purpose: Synaptic vesicle protein 2A (SV2A) constitutes a distinct...*3rd June, 2009
UCB Pharma S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.- *Epilepsia.* 2009 Apr 19. ([DOI Direct Link](#))
- [Behavioural phenotyping reveals anxiety-like features of SV2A deficient mice.](#)
*Synaptic vesicle protein 2A (SV2A) is involved in neurotransmitter release...*23rd April, 2009
Preclinical CNS Research, UCB Pharma s.a., Braine-l'Alleud, Belgium.- *Behav Brain Res.* 2009 Mar 17;198(2):329-33. Epub 2008 Nov 11. ([DOI Direct Link](#))
- [Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach.](#)
*The present study was undertaken to validate a battery of cytotoxicity...*15th April, 2009
UCB Pharma SA, Investigative Non-Clinical Safety, Non-Clinical- *Toxicol In Vitro.* 2009 Mar;23(2):319-32. Epub 2008 Dec 10. ([DOI Direct Link](#))
- [GPCRs in medicinal chemistry.](#)
*The present study was undertaken to validate a battery of cytotoxicity...*31st January, 2009
UCB Pharma SA,B-1420, Braine-l'Alleud, Belgium.- *IDrugs.* 2008 Dec;11(12):870-5.

Press Releases on UCB Pharma:

| | | | |
|--|---------------------|--------------|---|
| Reportlinker Adds Imaging Agents - A Worldwide Market Review | 20th November, 2009 | Reportlinker | NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Imaging Agents - A Worldwide Market Review http://www.reportlinker.com |
| Reportlinker Adds Medical Specialty Bags - Global Market Trends | 20th November, 2009 | Reportlinker | NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Medical Specialty Bags - Global Market Trends http://www.reportlinker.com |
| Time to Blow Up the Pharmaceutical Sales Model? New Deloitte Debate | 19th November, 2009 | Deloitte | NEW YORK, Nov. 19 /PRNewswire/ -- What: "New Commercial Model: Science or Swag?" Who: W. Scott Evangelista, principal, Deloitte Consulting LLP When: Available immediately Where: www |
| Reportlinker Adds Global Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 | 18th November, 2009 | Reportlinker | NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Global Dental Devices Investment Opportunities, Analysis and Forecasts to |
| Reportlinker Adds Intravenous Equipment - A World Market Intelligence Report | 18th November, 2009 | Reportlinker | NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Intravenous Equipment - A World Market Intelligence Report http://www |

BioNews Results for UCB Pharma



- [BioInvent Signs Licensing Agreement with Daiichi Sankyo for the Discovery and Development of Therapeutic Antibodies](#)
NewsBlaze: Nov 13 2009 10:55AM Matching: ucb pharma
- [Announcing the 9th Annual ePharma Summit February 8-10, 2010 Hyatt Regency at PennEURs Landing, Philadelphia](#)
Pharma Live: Nov 12 2009 12:04AM Matching: ucb pharma
- [Week of Nov. 9, 2009: Merck and Schering-Plough Begin Combined Operations; UCB Appoints VP; More](#)
Indianapolis Recorder: Nov 12 2009 1:28AM Matching: ucb pharma
- [Arthritis: Research from UCB Pharma S.A. has provided new information about arthritis](#)

- NewsRX: Nov 11 2009 5:09AM Matching: ucb pharma*
- [Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and Bank of America Corporation](#)
- Yahoo! Canada: Nov 11 2009 10:15PM Matching: ucb pharma*
- [Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and Bank of America Corporation](#)
- PR inside: Nov 11 2009 10:14PM Matching: ucb pharma*
- [Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and Bank of America Corporation](#)
- Business Wire UK: Nov 11 2009 10:12PM Matching: ucb pharma*
- [Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and Bank of America Corporation](#)
- Business Wire: Nov 11 2009 10:07PM Matching: ucb pharma*
- [This Latest Q4 2009 United Kingdom Pharmaceuticals and Healthcare Report Provides Independent Forecasts and Co](#)
- Pharmacy Choice: Nov 11 2009 2:14PM Matching: ucb pharma*
- [TRIN Pharma names Stefan Wohlfeil CEO](#)
- FierceBiotech: Nov 11 2009 3:49PM Matching: ucb pharma*
- [Week of Nov. 9, 2009: Merck and Schering-Plough Begin Combined Operations; UCB Appoints VP; More...](#)
- Pharmaceutical Technology: Nov 11 2009 6:44PM Matching: ucb pharma*
- [Antibody molecules having specificity for human IL-1.beta](#)
- PharmCast: Nov 9 2009 6:22AM Matching: ucb pharma*
- [Program for clinical outsourcing and development professionals](#)
- News-Medical.Net: Nov 4 2009 10:32AM Matching: ucb pharma*
- [Forecast Insight Fibromyalgia Regulatory caution threatens EU market expansion By Bharatbook.com](#)
- PRMinds: Oct 31 2009 8:23PM Matching: ucb pharma*
- [Research and Markets: This Latest Q4 2009 United Kingdom Pharmaceuticals and Healthcare Report Provides Indepe](#)
- Pharmacy Choice: Oct 30 2009 1:44AM Matching: ucb pharma*

UCB Pharma Patents:



- 7608694- [Antibody molecules having specificity for human IL-1.beta.](#)
- 7456286- [Bicyclic heteroaromatic compounds as kinase inhibitors](#)
- 7452976- [Biological products](#)
- 7419659- [Expression control using variable intergenic sequences](#)
- 7402662- [Antibody molecules specific to human tumor necrosis factor alpha](#)
- 7355011- [Biological products](#)
- 7300765- [SC6 for diagnosis of cancers](#)
- 7297760- [Cancer associated protein](#)
- 7273744- [Heparanase-like polypeptides](#)
- 7479283- [Acellular pertussis vaccine comprising a combination of the 69 kDa and the filamentous haemagglutinin antigens of Bordetella pertussis](#)

- 7488741- [4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments](#)
- 7601817- [Antibody peg positional isomers, compositions comprising same, and use thereof](#)
- 7592455- [Bicyclic heteroaromatic compounds as kinase inhibitors](#)
- 7563912- [Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues](#)
- 7557130- [Bicyclic heteroaromatic alanines](#)
- 7531549- [Phenylalanine enamide derivatives](#)
- 7521460- [Thienopyridone derivatives as kinase inhibitors](#)
- 7504353- [Hydrogenation catalysts](#)
- 7501437- [Phenylalanine enamide derivatives](#)
- 7169399- [Non-toxic double mutant forms of pertussis toxin as adjuvants](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,

